To Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With RRMS (GLOW)
This study has been terminated.
Study NCT01578785
Information provided by Teva Pharmaceutical Industries
First Received on March 13, 2012.
Last Updated on January 2, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
